Peter Kuhn, Ph.D.

Dean’s Professor of Convergent Sciences
Director, Southern California Physics Oncology Center
Co-Director, the BRIDGE @ USC

Dr. Kuhn is a scientist and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care.

Dr. Kuhn is the Dean’s Professor of Convergent Science at USC, a co-founder of the BRIDGE @ USC and director of the Southern California Physics Oncology Center. His research is shedding new light at how cancer spreads through the body. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. 

Leveraging the laboratory’s fluid biopsy technology innovation, the Southern California Physics Oncology Center is advancing daily the forefront of both improving healthcare effectiveness for cancer patients by providing drug guidance and increasing our understanding of cancer as a disease in each individual patient. The technology developed in the academic laboratory has been licensed to Epic Sciences to bring to market high precision diagnostic products.  

Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he later joined the faculties of Medicine and Accelerator Physics. From 2002 to 2014 he established a translational science program at the Scripps Research in La Jolla, CA that brought together over forty scientists from basic, engineering and medical sciences to work on understanding the spread of cancer in the human body. He has published over 200 peer scientific articles and patents as a result of his research.

The University of Southern California (USC) recruited Dr. Kuhn in 2014 to advance the next frontier of human scale science that can improve the human condition. At the convergence of biological, engineering and medical sciences will we learn how major diseases from cancer to neurodegenerative to autoimmune diseases evolve in and how we can improve the outcomes for patients.